Kenneth Bender, PharmD, MA

Occult HBV infection is likely to go undetected in under-resourced regions of high HBV endemicity and confound WHO goal to eradicate the viral hepatitis by 2030.

Progress in rapid diagnostic and point-of-care testing propelled by the pandemic can improve timeliness and precision of anti-infective treatment.

The same 5-year survival rates with kidney transplants from HCV positive and negative donors supports revising HCV "penalty" in ranking donors.

"Real-world" population study finds the oral antivirals authorized for non-hospitalized COVID-19 patients can benefit when started in the hospital.

Reviewers weigh evidence for the benefit of oral PrEP protection from HIV with risk of exacerbating hepatitis B.

Oral antiviral nirmatrelvir/ritonavir is shown to be effective treatment for seniors against Omicron.

The young adult contracting paralytic polio in Rockland County, New York in June is the first since the WHO declared the Americas polio-free in 1994.

WHO guidelines on HIV, hepatitis and STIs focus on populations with high risk of infections but low inclusion in prevention and treatment programs.

WHO issues new HCV treatment recommendations that include "radical simplification" of care pathways, in pursuit of testing and treatment goals.

CDC links 2021 outbreak of tuberculosis in US affecting 113 persons and causing at least 3 deaths to bone grafts from one infected, deceased donor.

Next generation antimalarial monoclonal antibody is three times more potent than predecessor in preventing parasitemia, stopping parasite replicating.

Finding that the COVID-19 pandemic disrupted best antibiotic practices, the CDC announced further efforts to curb treatment-resistant infections.

Implicating adenovirus for hepatitis of unknown cause in children is confounded by its absence in some cases, and from all tested hepatic tissue.

CDC attributes a 15% increase in deaths from antimicrobial-resistant infections in 2020 to impacts of COVID-19 on health and healthcare.

Work group from infectious disease associations proposes prioritizing 6 areas of research to improve efficacy and precision of antibiotic therapy

Investigational vaccine demonstrates efficacy against respiratory syncytial virus in trial with adults inoculated with active RSV.

Algorithm offers guidance on clinically managing pregnant individuals exposed to monkeypox and on treating the virus during pregnancy.

Carbapenem-resistant enterobacterales in Saudi Arabia were genotyped and the course of illness characterized to help inform treatment and prevention.

At separate press conferences, the CDC and WHO indicate that containing monkeypox will depend on testing, tracing, and currently available vaccines.

The first report from WHO Scientific Advisory Group for the Origins of Novel Pathogens (SAGO) concedes SARS-CoV-2 source remains a mystery.

Rebound in COVID-19 symptoms, retesting positive for SARS-CoV-2, and recurring infectivity after Paxlovid treatment mars "test and treat."

New vaccine for COVID-19 employing receptor-binding domain-dimer-based platform achieves 87.6% efficacy against severe to critical illness.

Community transmission of monkeypox outside traditional endemic regions of the virus prompts calls for increased vigilance.

Study links inappropriate, off-guideline antibiotics to increased, avoidable allergic and adverse events in children.

Active immunization of pregnant women with investigational vaccine protected infants from RSV from birth through at least 6 months.

Historically low incidence of dengue in southeast Asia and Latin America linked to COVID-19 restrictions suggests potential future interventions.

Correlating immune response to COVID-19 vaccination in persons with HIV to their CD4 T-cell count could inform optimal vaccine strategy.

Investigators consider the low rate of vaccination in the rapidly increasing migrant populations in Europe, and call for improved strategies.

Selecting initial antibiotic for ventilator-associated pneumonia from Gram staining and resistance records could reduce broad spectrum agents.

Adding v-safe active monitoring to VAERS passive reporting produced "most comprehensive" program, and affirmed COVID-19 vaccine safety.